Cargando…

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zifeng, Tian, Ruifeng, Zhang, Xiao-Jing, Cai, Jingjing, She, Zhi-Gang, Li, Hongliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877359/
https://www.ncbi.nlm.nih.gov/pubmed/36712249
http://dx.doi.org/10.3389/fcvm.2022.1120085
_version_ 1784878350849802240
author Yang, Zifeng
Tian, Ruifeng
Zhang, Xiao-Jing
Cai, Jingjing
She, Zhi-Gang
Li, Hongliang
author_facet Yang, Zifeng
Tian, Ruifeng
Zhang, Xiao-Jing
Cai, Jingjing
She, Zhi-Gang
Li, Hongliang
author_sort Yang, Zifeng
collection PubMed
description In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors and/or by boosting systemic inflammation, releasing other secretory factors, and having an expansion of epicardial adipose tissue (EAT). Therefore, the treatments of NAFLD may also affect the development and prognosis of HFpEF. However, no specific drugs for NAFLD have been approved by the Food and Drug Administration (FDA) and some non-specific treatments for NAFLD are applied in the clinic. Currently, the treatments of NAFLD can be divided into non-pharmacological and pharmacological treatments. Non-pharmacological treatments mainly include dietary intervention, weight loss by exercise, caloric restriction, and bariatric surgery. Pharmacological treatments mainly include administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and metformin. This review will mainly focus on analyzing how these treatments may affect the development and prognosis of HFpEF.
format Online
Article
Text
id pubmed-9877359
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98773592023-01-27 Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction Yang, Zifeng Tian, Ruifeng Zhang, Xiao-Jing Cai, Jingjing She, Zhi-Gang Li, Hongliang Front Cardiovasc Med Cardiovascular Medicine In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors and/or by boosting systemic inflammation, releasing other secretory factors, and having an expansion of epicardial adipose tissue (EAT). Therefore, the treatments of NAFLD may also affect the development and prognosis of HFpEF. However, no specific drugs for NAFLD have been approved by the Food and Drug Administration (FDA) and some non-specific treatments for NAFLD are applied in the clinic. Currently, the treatments of NAFLD can be divided into non-pharmacological and pharmacological treatments. Non-pharmacological treatments mainly include dietary intervention, weight loss by exercise, caloric restriction, and bariatric surgery. Pharmacological treatments mainly include administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and metformin. This review will mainly focus on analyzing how these treatments may affect the development and prognosis of HFpEF. Frontiers Media S.A. 2023-01-12 /pmc/articles/PMC9877359/ /pubmed/36712249 http://dx.doi.org/10.3389/fcvm.2022.1120085 Text en Copyright © 2023 Yang, Tian, Zhang, Cai, She and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Yang, Zifeng
Tian, Ruifeng
Zhang, Xiao-Jing
Cai, Jingjing
She, Zhi-Gang
Li, Hongliang
Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
title Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
title_full Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
title_fullStr Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
title_full_unstemmed Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
title_short Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
title_sort effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877359/
https://www.ncbi.nlm.nih.gov/pubmed/36712249
http://dx.doi.org/10.3389/fcvm.2022.1120085
work_keys_str_mv AT yangzifeng effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction
AT tianruifeng effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction
AT zhangxiaojing effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction
AT caijingjing effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction
AT shezhigang effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction
AT lihongliang effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction